[go: up one dir, main page]

DK3325487T3 - Formulering til bløde, anticholinerge analoger - Google Patents

Formulering til bløde, anticholinerge analoger Download PDF

Info

Publication number
DK3325487T3
DK3325487T3 DK16828553.4T DK16828553T DK3325487T3 DK 3325487 T3 DK3325487 T3 DK 3325487T3 DK 16828553 T DK16828553 T DK 16828553T DK 3325487 T3 DK3325487 T3 DK 3325487T3
Authority
DK
Denmark
Prior art keywords
anticholinerge
analogs
formulation
soft
anticholinerge analogs
Prior art date
Application number
DK16828553.4T
Other languages
English (en)
Inventor
John J Koleng
David Angulo
Nicholas S Bodor
Original Assignee
Bodor Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bodor Laboratories Inc filed Critical Bodor Laboratories Inc
Priority claimed from PCT/US2016/043380 external-priority patent/WO2017015485A1/en
Application granted granted Critical
Publication of DK3325487T3 publication Critical patent/DK3325487T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00Anti-perspirants or body deodorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
DK16828553.4T 2014-03-13 2016-07-21 Formulering til bløde, anticholinerge analoger DK3325487T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461952505P 2014-03-13 2014-03-13
US14/805,114 US20150320722A1 (en) 2014-03-13 2015-07-21 Formulation for soft anticholinergic analogs
PCT/US2016/043380 WO2017015485A1 (en) 2015-07-21 2016-07-21 Formulation for soft anticholinergic analogs

Publications (1)

Publication Number Publication Date
DK3325487T3 true DK3325487T3 (da) 2021-08-02

Family

ID=54068191

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15762178.0T DK3116498T3 (da) 2014-03-13 2015-03-12 Formulering til bløde anticholinerge analoger
DK16828553.4T DK3325487T3 (da) 2014-03-13 2016-07-21 Formulering til bløde, anticholinerge analoger

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15762178.0T DK3116498T3 (da) 2014-03-13 2015-03-12 Formulering til bløde anticholinerge analoger

Country Status (20)

Country Link
US (8) US20150259283A1 (da)
EP (1) EP3116498B1 (da)
JP (5) JP6293919B2 (da)
KR (3) KR102586868B1 (da)
CN (3) CN106456603B (da)
AU (2) AU2015229243B2 (da)
BR (1) BR112016021011B1 (da)
CA (1) CA2941649C (da)
DK (2) DK3116498T3 (da)
ES (1) ES2710292T3 (da)
HU (1) HUE041868T2 (da)
IL (1) IL247571B (da)
MX (1) MX369129B (da)
MY (1) MY183531A (da)
PH (1) PH12016501732B1 (da)
PL (1) PL3116498T3 (da)
PT (2) PT3116498T (da)
SG (1) SG11201607480SA (da)
WO (1) WO2015138776A1 (da)
ZA (1) ZA201607071B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1861112A4 (en) * 2005-03-03 2009-07-22 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINES
ES2836132T3 (es) 2013-08-08 2021-06-24 Novan Inc Composiciones tópicas y métodos de uso de las mismas
US20150259283A1 (en) 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
AU2016297601B2 (en) 2015-07-21 2021-08-19 Bodor Laboratories, Inc. Formulation for soft anticholinergic analogs
TWI719046B (zh) * 2016-07-21 2021-02-21 美商波德實驗股份有限公司 軟性抗膽鹼類似物之製劑
US11381304B2 (en) * 2017-08-30 2022-07-05 Iridium Satellite Llc Satellite communications with multiple classes of terrestrial terminal devices
TWI838531B (zh) * 2019-05-23 2024-04-11 日商科研製藥股份有限公司 索吡銨溴化物的結晶形態及其製造方法
SG10201912063PA (en) * 2019-12-12 2021-07-29 Nat Skin Centre Singapore Pte Ltd A pharmaceutical formulation
JPWO2021177257A1 (da) 2020-03-03 2021-09-10
TW202146009A (zh) 2020-03-03 2021-12-16 日商科研製藥股份有限公司 含有溴化索非羅銨的醫藥
KR102655121B1 (ko) 2021-09-17 2024-04-08 한국식품연구원 락토바실러스 사케이 k040706 균주 검출용 프라이머 세트 및 이의 용도
US11807604B1 (en) * 2022-02-16 2023-11-07 Miralogx Llc Pharmaceutical compounds, pharmaceutical compositions, and methods of treating asthma and other disorders
WO2024026412A1 (en) * 2022-07-28 2024-02-01 Tff Pharmaceuticals, Inc. Thin film freezing methods and compositions formulated from dispersed active agents
KR102611847B1 (ko) * 2023-03-27 2023-12-12 주식회사 이플라스크 무스카린 수용체 길항 활성을 갖는 신규한 피롤리디늄 화합물 및 이의 용도

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149832C (da) * 1981-07-17 1987-05-18 Riemann Claus Antiperspirantpraeparat bestaaende af to komponenter
DK483587D0 (da) * 1987-09-15 1987-09-15 Riemann & Co Aps Claus Antiperspirant praeparat
US5292530A (en) * 1991-06-02 1994-03-08 Helene Curtis, Inc. Stable anhydrous topically-active composition and suspending agent therefor
CA2014633C (en) * 1989-06-02 2000-07-18 Andrew D. Mccrea Stable anhydrous compositions for topical delivery of active materials
US5232689A (en) * 1990-12-21 1993-08-03 Dow Corning Corporation Translucent antiperspirant compositions
US5143719A (en) 1991-04-16 1992-09-01 Chesebrough-Pond's Usa Co. Anticalculus oral composition containing combinations of organophosphorus polycarboxylate cotelomers and inorganic polyphosphate salts
CA2128063A1 (en) 1993-07-16 1995-01-17 Virgil A. G. Williams Stable, clear antiperspirant composition and method of use
US5895644A (en) * 1997-11-20 1999-04-20 Colgate-Palmolive Company Clear antiperspirant stick with dibenzylidene sorbitol and guar and process of making same
US6433003B1 (en) 1999-04-23 2002-08-13 Arthur M. Bobrove Method for treating hyperhidrosis in mammals
US6319491B1 (en) 2000-04-11 2001-11-20 Michael B. Whipple Anti-sweat lotion
US20030064040A1 (en) * 2001-09-26 2003-04-03 Lukacsko Alison B. Compositions and methods for inhibiting eccrine perspiration in humans
JP2003113392A (ja) 2001-10-04 2003-04-18 Kiyomitsu Kawasaki 芳香・消臭組成物および該芳香・消臭組成物を含有する人体用芳香・消臭剤
US8252316B2 (en) * 2002-05-03 2012-08-28 Purepharm Inc. Method of topically applying glycopyrrolate solution using absorbent pad to reduce sweating
BR0308051A (pt) 2003-12-15 2005-09-06 Natura Cosmeticos Sa Composição base para preparação de formulações multifuncionais para o cuidado e proteção da pele e cabelo
US20060088496A1 (en) * 2004-10-25 2006-04-27 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Personal care compositions with salts of hydroxypropyl trialkylammonium substituted mono-saccharide
US7087560B2 (en) * 2004-10-25 2006-08-08 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Personal care composition with salts of dihydroxypropyltri(C1-C3 alkyl) ammonium monosubstituted polyols
GB0428418D0 (en) * 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0428416D0 (en) * 2004-12-24 2005-02-02 Novartis Ag Organic compounds
US8343467B2 (en) * 2004-12-27 2013-01-01 Beiersdorf Ag Glycopyrrolate in cosmetic preparations
US10010494B2 (en) * 2005-10-19 2018-07-03 Menni Menashe Zinger Methods for the treatment of hyperhidrosis
US7417147B2 (en) 2005-11-10 2008-08-26 Bodor Nicholas S Soft anticholinergic zwitterions
CA2627982C (en) 2005-11-10 2013-09-10 Nicholas S. Bodor Soft anticholinergic esters
AU2006201878A1 (en) * 2006-03-13 2007-09-27 Foamix Ltd Foamable composition for hyperhidrosis
JP5371235B2 (ja) * 2006-12-06 2013-12-18 ロート製薬株式会社 皮膚外用剤
US10265265B2 (en) * 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
US8618160B2 (en) 2007-10-18 2013-12-31 Rose U Topical glycopyrrolate formulations
US20100137357A1 (en) * 2008-11-26 2010-06-03 Koleng John J Compositions and methods for hyperhidrosis
US20140037713A1 (en) * 2012-08-03 2014-02-06 Antares Pharma Ipl, Ag Transdermal compositions for anti-cholinergic agents
WO2014144075A1 (en) * 2013-03-15 2014-09-18 Bodor Laboratories, Inc. Anticholinergic glycopyrrolate esters for the treatment of hyperhidrosis
US20150259283A1 (en) 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
WO2015138700A1 (en) 2014-03-13 2015-09-17 Bodor Laboratories, Inc. Use of selected anticholinergic zwitterions
AU2016297601B2 (en) 2015-07-21 2021-08-19 Bodor Laboratories, Inc. Formulation for soft anticholinergic analogs
TWI719046B (zh) 2016-07-21 2021-02-21 美商波德實驗股份有限公司 軟性抗膽鹼類似物之製劑

Also Published As

Publication number Publication date
US20210078946A1 (en) 2021-03-18
MX2016011529A (es) 2016-12-07
PT3325487T (pt) 2021-07-29
IL247571A0 (en) 2016-11-30
US10947192B2 (en) 2021-03-16
CA2941649A1 (en) 2015-09-17
KR20160133492A (ko) 2016-11-22
JP6762047B2 (ja) 2020-09-30
PT3116498T (pt) 2019-02-11
DK3116498T3 (da) 2019-03-11
AU2019257421B2 (en) 2021-10-21
SG11201607480SA (en) 2016-10-28
ZA201607071B (en) 2018-12-19
PH12016501732A1 (en) 2017-02-06
JP2018115203A (ja) 2018-07-26
ES2710292T3 (es) 2019-04-24
US20210087142A1 (en) 2021-03-25
JP6756763B2 (ja) 2020-09-16
CN110917124A (zh) 2020-03-27
US20150320722A1 (en) 2015-11-12
EP3116498A1 (en) 2017-01-18
EP3116498B1 (en) 2018-12-12
IL247571B (en) 2020-03-31
US11034652B2 (en) 2021-06-15
JP2017214429A (ja) 2017-12-07
JP6293919B2 (ja) 2018-03-14
JP2020079321A (ja) 2020-05-28
KR102586868B1 (ko) 2023-10-11
PH12016501732B1 (en) 2017-02-06
CN106456603A (zh) 2017-02-22
US20170020845A1 (en) 2017-01-26
HUE041868T2 (hu) 2019-05-28
JP2019189650A (ja) 2019-10-31
BR112016021011A8 (pt) 2021-07-20
CN110917124B (zh) 2023-06-20
US11084788B2 (en) 2021-08-10
CN110420167B (zh) 2023-02-17
AU2019257421A1 (en) 2019-11-21
AU2015229243A1 (en) 2016-10-20
CN106456603B (zh) 2020-01-10
US20150259283A1 (en) 2015-09-17
KR102433868B1 (ko) 2022-08-19
JP2017507970A (ja) 2017-03-23
WO2015138776A1 (en) 2015-09-17
JP6461267B2 (ja) 2019-01-30
US20200093791A1 (en) 2020-03-26
KR20220119517A (ko) 2022-08-29
US20200113869A1 (en) 2020-04-16
US20210198195A1 (en) 2021-07-01
BR112016021011B1 (pt) 2022-12-13
AU2015229243B2 (en) 2019-11-21
MX369129B (es) 2019-10-30
CN110420167A (zh) 2019-11-08
CA2941649C (en) 2021-03-02
EP3116498A4 (en) 2017-11-08
BR112016021011A2 (pt) 2017-08-15
US10961191B2 (en) 2021-03-30
KR20230145522A (ko) 2023-10-17
MY183531A (en) 2021-02-25
PL3116498T3 (pl) 2019-05-31
US12398102B2 (en) 2025-08-26

Similar Documents

Publication Publication Date Title
DK3325487T3 (da) Formulering til bløde, anticholinerge analoger
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3461821T3 (da) Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
LT3134402T (lt) 4-amino-imidazochinolino junginiai
DK3722274T3 (da) 2-perfluorbutylpentan til oftalmisk indgivelse
DK3218504T3 (da) Trisegmenterede arenavira som vaccinevektorer
DK3194411T3 (da) Nukleotidanaloger
BR112016023628A2 (pt) composições farmacêuticas.
DK3130649T3 (da) Haloolefin-baseret sammensætning
DK3125898T3 (da) Farmakofor til trail-induktion
FR3024363B1 (fr) Composition thermogelifiable
EP3237013C0 (en) TRANSDERMAL FORMULATIONS
HUE054245T2 (hu) Immunszupresszáns formuláció
DK3230929T3 (da) Forbedringer til tælleranordninger
DK3197890T3 (da) Disubstituerede diaryloxybenzoheterodiazolforbindelser
DK3153508T3 (da) Naphthofuranderivater til anvendelse som anticancermidler
DK3265394T3 (da) Fremgangsmåde til emballering
CL2017000639A1 (es) Composición
DK3277690T3 (da) Spirocykliske forbindelser
DK3191466T3 (da) Azetidinyloxyphenylpyrrolidinforbindelser
HRP20181530T1 (hr) Novi sulfonilaminobenzamidni spojevi
LT3253749T (lt) Junginiai, pasižymintys priešnavikiniu aktyvumu
DK3792251T3 (da) Hidtil ukendte sulfonylaminobenzamidforbindelser som anthelmintika
EP3236746C0 (en) COMPOSITION
BR112016017925A2 (pt) Formulação de colagem estabilizada